While statins have long been the backbone of heart‑health treatment, doctors are increasingly highlighting the role of GLP‑1 medications as a complementary option. The use of GLP‑1 drugs has quadrupled in recent years, and emerging research points to several cardiovascular advantages beyond weight loss.
How GLP‑1s and statins differ
Statins lower LDL (“bad”) cholesterol by blocking a liver enzyme, slowing plaque buildup and reducing heart‑attack and stroke risk. GLP‑1 drugs, on the other hand, mimic a natural hormone that regulates blood sugar, appetite and feelings of fullness. By promoting weight loss and improving blood sugar, triglycerides, blood pressure and inflammation, GLP‑1s address metabolic factors that strain the cardiovascular system.
Cardiologists’ perspective
Dr. Arash Bereliani, a cardiologist and medical director at the Beverly Hills Institute for Cardiology and Preventive Medicine, explains, “I tell patients to think of the statin as the foundation for cholesterol and the GLP‑1 as handling the metabolic side.” He adds that using both therapies can cover more ground than either alone.
Dr. Fadi Alameddine of Houston Methodist Cypress Hospital echoes this view, noting, “Statins drop LDL cholesterol by 30 to 50 percent, and we have decades of data confirming fewer heart attacks. GLP‑1s barely touch LDL, but they work on weight, inflammation, blood sugar, blood pressure and vascular health.”
Beyond weight loss
Research published in The New England Journal of Medicine showed that semaglutide, the active ingredient in Ozempic, lowered high‑sensitivity C‑reactive protein (hs‑CRP), a marker of inflammation, within four to eight weeks—often before significant weight loss occurred. Dr. Alameddine says this suggests the drug’s anti‑inflammatory effects are not solely due to weight reduction.
GLP‑1s also appear to improve endothelial function, the thin lining of blood vessels, and increase nitric oxide production, which helps vessels relax and reduces oxidative stress. These changes can keep arteries more flexible and less prone to plaque formation.
Blood‑pressure and kidney effects
Patients on GLP‑1 therapy typically see modest drops in blood pressure, partly from weight loss and partly from increased sodium excretion by the kidneys. Less sodium means less water retention, which can lower circulating blood volume and reduce pressure on vessel walls.
Metabolic improvements
GLP‑1 drugs improve several metabolic markers: triglycerides decline, good cholesterol (HDL) rises slightly, and blood sugar control improves markedly. One study found semaglutide users were 73 % less likely to develop diabetes than those on placebo. Better glucose control protects blood vessels from damage that contributes to heart disease.
Reducing harmful fat around the heart
By decreasing visceral fat, GLP‑1s also reduce epicardial fat—the layer of fat that surrounds the heart. This fat is metabolically active and releases inflammatory substances that can harm the heart and vessels.
Putting it into practice
Dr. Bereliani says many men first bring concerns about weight, energy and appearance to his office. He uses GLP‑1 therapy as an entry point to discuss broader heart health, emphasizing that losing belly fat can directly lower cardiovascular risk.
In summary, while statins remain essential for lowering LDL cholesterol, GLP‑1 medications provide a multi‑faceted approach to heart health by tackling weight, inflammation, blood pressure, blood sugar and vascular function. Cardiologists suggest that, for the right patients, a combined regimen may offer the most comprehensive protection against heart disease.
Original reporting: WPBF (Treasure Coast / Hearst) — read the source article.
